GIHCG and cervical carcinoma: lncRNA GIHCG, highly expressed in cervical cancer, can distinguish cervical cancer patients from healthy controls with a sensitivity and specificity of 88.75 and 87.50%, respectively, making it a possible diagnostic biomarker [104].